LP-50 is an intravesical formulation for local, intravesical PD-1 (i.e. checkpoint) inhibition, intended for the treatment of non muscle invasive bladder cancer (NMIBC). Intravesical immunotherapy presents a promising avenue for bladder cancer treatment, offering the potential for increasing efficacy while minimizing systemic toxicity.